Preclinical development of a miR-132 inhibitor for heart failure treatment
miR-132 was shown to drive pathological cardiac remodeling, a hallmark of heart failure. Here, the authors show that an antisense inhibitor of miR-132 has favourable pharmacokinetics, safety-tolerability and preclinical efficacy in mouse and porcine models of heart failure.
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2020-01-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-020-14349-2 |